Leveraging assets & ideas
A deal between Cytokinetics Inc. and Exelixis Inc. to establish small molecule compound libraries marks another example of a collaboration where two biotech companies share ideas and competencies in a narrowly defined area that should make both companies better off. At the same time, it's an opportunity for EXEL to monetize its investment in compound libraries.
As announced last week, the companies will jointly design and develop small molecule libraries for use in their respective drug discovery programs. EXEL (South San Francisco, Calif.) will synthesize the library using its combinatorial chemistry platform, whereas Cytokinetics (South San Francisco, Calif.) will bring in its ideas for small molecule compound library design and finances. ...